Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast ...
The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, ...
David Roche of Quantum Strategy told CNBC’s Squawk Box Asia that bubbles in AI and credit markets are beginning to crack, ...
Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...
The nods allow Regeneron to better compete with Roche, which stormed the market in 2022 with Vabysmo. The Swiss drugmaker's ...
The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.
Roche's oral selective oestrogen receptor degrader (SERD) giredestrant has achieved what the company says is a stellar result ...
Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim ...
The approval puts Lunsumio on the same footing as Epkinly (epcoritamab) in FL – a form of non-Hodgkin lymphoma (NHL) – as ...
Indianapolis-based Roche Diagnostics said while the survey was conducted in Europe, its implications are global and reflect ...
Roche's experimental multiple sclerosis drug achieved its main goal in one of two key late-stage trials testing it against ...
Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback